GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » 6-1 Month Momentum %

Protara Therapeutics (Protara Therapeutics) 6-1 Month Momentum % : 105.52% (As of Jun. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-01), Protara Therapeutics's 6-1 Month Momentum % is 105.52%.

The industry rank for Protara Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

TARA's 6-1 Month Momentum % is ranked better than
92.78% of 1523 companies
in the Biotechnology industry
Industry Median: -4.94 vs TARA: 105.52

Competitive Comparison of Protara Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Protara Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protara Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's 6-1 Month Momentum % falls into.



Protara Therapeutics  (NAS:TARA) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protara Therapeutics  (NAS:TARA) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Protara Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Protara Therapeutics (Protara Therapeutics) Business Description

Traded in Other Exchanges
Address
345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Executives
Patrick Fabbio officer: Chief Financial Officer 2 PITNEY COURT, BASKING RIDGE NJ 07920
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Jesse Shefferman director, officer: CEO and President C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry officer: VP, Controller 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari officer: Chief Medical Officer C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo officer: Chief Medical Officer C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall 10 percent owner C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly director ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julio Casoy officer: Chief Medical Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Jacqueline Zummo officer: Sr. Vice President, Research C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014

Protara Therapeutics (Protara Therapeutics) Headlines

From GuruFocus

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

By Stock market mentor Stock market mentor 01-30-2023